Dhruvi Joshi: Reduced-Dose DOAC Therapy in Patients With Venous Thromboembolism
Dhruvi Joshi, Founder and Creator at The 25th Hour Project, shared a post on LinkedIn about a recent article she and her colleagues co-authored, published in JSCAI, adding:
“Thrilled to share our meta-analysis, now published in the Journal of the Society for Cardiovascular Angiography and Interventions (JSCAI)!
Across 5 RCTs involving 8,781 patients with VTE, reduced-dose DOACs demonstrated a significant reduction in major bleeding (1.2% vs 2.0%; RR 0.62; p=0.019) and clinically relevant non-major bleeding (5.2% vs 7.0%; RR 0.75; p<0.001), with no significant difference in recurrent VTE (RR 0.92) or all-cause mortality (RR 0.86) compared to full-dose regimens.
Results were consistent across patients with and without active cancer.
My sincerest gratitude to Dr. Saraschandra Vallabhajosyula, for his invaluable mentorship and guidance through every step of the way.
Beyond grateful to Dr. Zeeshan Mansuri, Siddharth Pravin Agrawal, Hritvik Jain, Zaraith Coy Neira, Mir wajid Majeed and Caroline Serafim Dagostin for their support.”
Title: Reduced-Dose vs Full-Dose Direct Oral Anticoagulants for Extended Anticoagulation Therapy in Patients With Venous Thromboembolism: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Authors: Dhruvi K. Joshi, Najwaa Kirmani, Zaraith Coy, Siddharth P. Agrawal, Mir W. Majeed, Caroline Dagostin, Hritvik Jain, Zeeshan Mansuri, Peter A. Soukas, J. Dawn Abbott, Saraschandra Vallabhajosyula

Stay updated on all scientific advances with Hemostasis Today.
-
Jul 13, 2026, 11:25Luisa Müller: Advancing Anticoagulation Strategies for VITT at ISTH 2026
-
Jul 13, 2026, 10:49Joshua Zeidner: Advancing Menin Inhibitor Therapy in MD Education AML-ALL US Focus 2026
-
Jul 13, 2026, 10:25Flora Peyvandi: A Practical Approach to ALT Elevation After Gene Therapy at ISTH 2026
-
Jul 13, 2026, 10:02Jessica Garcia: Where Science and Community Come Together at ISTH 2026
-
Jul 13, 2026, 09:46Fabrice Cognasse: Is There Such a Thing as the Perfect Platelet Product?
-
Jul 13, 2026, 09:42Cancer-Associated Arterial Thromboembolism: Redefining the Thrombotic Burden in Oncology
-
Jul 13, 2026, 05:59Connecting and Collaborating at ISTH 2026 – NNHF
-
Jul 13, 2026, 05:58Lara Monica: Back at ISTH – Looking Forward to Science and Reconnections!
-
Jul 13, 2026, 05:57Barbara Adams Krolak: Exciting Updates From the ISTH 2026 Regulatory Session